OptimizeRx Corporation
NASDAQ:OPRXMedical - Healthcare Information Services
-$0.05 today
- Market cap
- $138.21M
- Beta
- 1.10
- P/E (TTM)
- 13.8
- EPS (TTM)
- $0.36
Volume 0.18M
Average 0.47M
OPRX Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
OptimizeRx CorporationNASDAQ: OPRX
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow turns negative
Q1 FY2026 free cash flow was -$488K, compared with $3.84M a year earlier. Trailing-twelve-month free cash flow was $14.33M. Over 3 fiscal years it compounded at +21.5% a year.
Context
- Free cash flow amounted to 17.0% of revenue in FY2025, up 11.9 pp from a year earlier.
- Free cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly free cash flow holds near -$488K or moves back toward the trailing-twelve-month quarterly average of $3.58M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 18.66M USD
- Year-over-year change
- +290.6%
- 4-year CAGR
- +196.9%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 18.66M | +290.6% |
| FY2024 | 2024-12-31 | 4.78M | +158.9% |
| FY2023 | 2023-12-31 | (8.11M) | -177.9% |
| FY2022 | 2022-12-31 | 10.41M | +4236.6% |
| FY2021 | 2021-12-31 | 240.04K | — |
Free Cash Flow vs competitors
How OPRX compares with its peers on the latest reported figures
- Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +127.1% is the 4th highest of 10, against a peer median of +16.7%.
- Free cash flow amounts to 13.4% of revenue for OPRX, versus a peer median of 17.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $45.99M USD | +1079.1% | +272.9% | 1173.4% | |
| LTM Mar 2026 | $45.43M USD | -2.6% | -21.7% | 56.0% | |
| LTM Mar 2026 | $41.97M USD | +95.1% | +39.9% | 12.1% | |
| LTM Mar 2026 | $37.06M USD | -22.6% | +10.8% | 15.6% | |
| LTM Mar 2026 | $25.53M USD | -2.2% | +111.1% | 18.7% | |
| LTM Feb 2026 | $22.87M USD | +130.8% | +7.7% | 28.4% | |
| LTM Mar 2026 | $21.58M USD | +5.2% | -31.9% | 16.9% | |
| LTM Mar 2026 | CA$20.08M CAD | +384.8% | -13.8% | — | |
| LTM Mar 2026 | $17.43M USD | +16.7% | -15.9% | 12.6% | |
| LTM Mar 2026 | $14.33M USD | +127.1% | +21.5% | 13.4% | |
| Peer median (excluding OPRX) | — | +16.7% | +7.7% | 17.8% | |
Competitors are the stored peer set for OPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 378.08K | (11.44M) | (17.57M) | (20.11M) | 5.13M |
| Depreciation & Amortization | 1.97M | 2.02M | 2.4M | 4.33M | 4.33M |
| Deferred Income Tax | 0 | 0 | 0 | 1.45M | 1.21M |
| Stock-Based Compensation | 5.49M | 15.75M | 13.72M | 11.47M | 6.96M |
| Change in Working Capital | (7.19M) | 3.96M | (15.55M) | 921K | 816K |
| Accounts Receivables | (6.99M) | 2.28M | (8.71M) | (2.17M) | 460K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (603.09K) | 555.4K | 195K | (72K) | (520K) |
| Other Working Capital | 408.65K | 1.12M | (7.03M) | 3.16M | 876K |
| Other Non-Cash Items | 80K | 363.51K | 9.76M | 6.83M | 264K |
| Operating Cash Flow | 726.04K | 10.65M | (7.24M) | 4.89M | 18.72M |
| Capital Expenditures | (486K) | (244.57K) | (871K) | (112K) | (58K) |
| Acquisitions (Net) | 0 | (2M) | (80.41M) | 0 | 0 |
| Purchases of Investments | 0 | (55.93M) | (162.78M) | 0 | 0 |
| Sales of Investments | 0 | 0 | 218.71M | 0 | 0 |
| Other Investing Activities | (385.68K) | (163.56K) | (774K) | (338K) | 126K |
| Investing Cash Flow | (486K) | (58.18M) | (25.34M) | (450K) | 68K |
| Debt Repayment | 0 | 0 | 36.02M | (4M) | (8M) |
| Common Stock Issued | 70.67M | 0 | 0 | 0 | 352K |
| Common Stock Repurchased | 0 | (20.02M) | (7.52M) | (911K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.25M | 1.07M | (278K) | 0 | (1.15M) |
| Financing Cash Flow | 73.92M | (18.95M) | 28.22M | (4.91M) | (8.8M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 74.16M | (66.47M) | (4.36M) | (472K) | 9.99M |
| Free Cash Flow | 240.04K | 10.41M | (8.11M) | 4.78M | 18.66M |
OptimizeRx Corporation
NASDAQ:OPRX
Intrinsic Alpha fair value
Locked
Current Price
$7.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.